
Helle Kristine Skjerven
- Head of section; MD, PhD
Publications 2025
Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives
Clin Breast Cancer, 25 (6), e721-e730
DOI 10.1016/j.clbc.2025.04.011, PubMed 40348620
Publications 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
Future Oncol, 20 (32), 2457-2466
DOI 10.1080/14796694.2024.2377531, PubMed 39073142
Publications 2023
Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics
Breast Cancer Res Treat, 201 (2), 247-256
DOI 10.1007/s10549-023-06986-0, PubMed 37355527
Long-term follow-up of complex oncoplastic breast-conserving surgery, standard breast conservation and skin-sparing mastectomy in DCIS - a register-based study
Eur J Surg Oncol, 50 (2), 107938
DOI 10.1016/j.ejso.2023.107938, PubMed 38199004
Coping After Breast Cancer: Protocol for a Randomized Controlled Trial of Stress Management eHealth Interventions
JMIR Res Protoc, 12, e47195
DOI 10.2196/47195, PubMed 37103493
Publications 2022
Normal and unusual days for dietary intake during the 12 months after a breast cancer diagnosis in women
Eur J Nutr, 61 (8), 3873-3885
DOI 10.1007/s00394-022-02925-9, PubMed 35750881
Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018
Breast Care (Basel), 17 (5), 486-494
DOI 10.1159/000524564, PubMed 36684407
Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women
Eur J Surg Oncol, 49 (3), 575-582
DOI 10.1016/j.ejso.2022.11.594, PubMed 36509629
Publications 2020
Dietary changes in early-stage breast cancer patients from pre-surgery and over the 12 months post-surgery
Br J Nutr, 125 (2), 172-182
DOI 10.1017/S0007114520002627, PubMed 32811572
Surgical treatment of breast cancer in Norway 2003-2018
Tidsskr Nor Laegeforen, 140 (15)
DOI 10.4045/tidsskr.20.0090, PubMed 33118768
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909
Publications 2017
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444
Publications 2015
Radiologic evaluation of lumps in the male breast
Acta Radiol, 57 (7), 809-14
DOI 10.1177/0284185115609802, PubMed 26543053